CompletedNCT00080314
Aripiprazole for depression in bipolarity type I
About this title
Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode
Read the official source — NCT00080314Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Tuscaloosa and 27 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJanuary 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 400
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00080314
- Official title
Show the full official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tuscaloosa · Little Rock · San Diego
25 more locations
- Sherman Oaks
- Norwich
- West Haven
- Jacksonville
- Maitland
- Orlando
- Honolulu
- Chicago
- Lake Charles
- Rockville
- Durham
- Raleigh
- Beachwood
- Dayton
- Oklahoma City
- Portland
- Media
- Memphis
- Austin
- Dallas
- Houston
- Lake Jackson
- Wichita Falls
- Arlington
- Bellevue
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
